A Pilot Clinical Trial of Postoperative Adjuvant Intraperitoneal Cisplatin,5-Fluorouracil,6S-Leucovorin and Interferon Alpha 2b in Patients with Resected Gastric Cancer
Restricted accessResearch articleFirst published online October, 1993
A Pilot Clinical Trial of Postoperative Adjuvant Intraperitoneal Cisplatin,5-Fluorouracil,6S-Leucovorin and Interferon Alpha 2b in Patients with Resected Gastric Cancer
The study was performed to assess the toxicity and impact on relapse pattern of postoperative intraperitoneal cisplatin, 5-fluorouracil, leucovorin and interferon therapy as adjuvant treatment for gastric cancer patients who are at high risk for recurrence after potentially curative resection (T2 N1-2; T3-4 N any Mo).
Patients and Methods
Starting 14 to 21 days after potentially curative resection of primary gastric cancers, 22 patients were given intraperitoneal cisplatin, 60 mg/m2; 5-fluorouracil, 1000 mg/m2; 6S-leucovorin, 250 mg/m2; interferon alpha 2b, 10 MU/m2; every other week for six times.
Results
After a median follow-up of 24 months, 63 % of patients were alive and free of disease. Eight patients had recurred; five had an intraabdominal component, and 3 had extraabdominal failure. Toxicity was mild: no grade III-IV WHO toxicity was observed.
Conclusions
Intraperitoneal cisplatin, 5-fluorouracil, 6S-leucovorin and interferon is a tolerable therapy in the postoperative setting for patients with resected gastric cancer. These data make this approach interesting for the development of new programs of adjuvant therapy of high-risk gastric cancer.
ArbuckS.G., DouglassH.O., TraveF., RustumY.M.: A phase II trial of 5-fluorouracil and high-dose leucovorin in gastric carcinoma and a phase I trial of intraperitoneal 5-fluorouracil and leucovorin. NCI Monogr., 5: 203–205, 1987.
2.
ArcherS., GrayB.: Intraperitoneal 5-fluorouracil infusion for treatment of both peritoneal and liver micrometastases. Surgery, 108: 502–507, 1990.
3.
AtiqO.T., KelsenD.P., ShiuM.H., SaltzL., TongW., NiedzwickiD., TrochanowskiB., LinS., ToomasiF., BrennanM.: Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J. Cin. Oncol., 11: 425–433, 1993.
4.
ComisR.L., CarterS.K.: Integration of chemotherapy into combined modality treatment of solid tumors: III. Gastric cancer. Cancer Treat. Rev., 1: 221, 1974.
5.
De BraudF., BajettaE., Di BartolomeoM., ColleoniM.: Adjuvant chemotherapy for cancer of gastrointestinal tract: a critical review. Tumori, 78: 228–234, 1992.
6.
FrasciG., PacelliR., ScalaS., FacchiniG., RinaldiL., TinessaV., BiancoA.R., IaffaioliR.V.: Intraperitoneal mitoxantrone via temporary catheter in patients with ovarian cancer: Toxicity and feasibility evaluation. Adv. Ther., 7: 124–135, 1990.
7.
GundersonL.L., SosinH.: Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys., 8: 1–11, 1982.
8.
HowellS.B., PfeifleC.E., WungW.E., OlshenR.A.: Intraperitoneal cisplatin with systemic thiosulfate protection. Cancer Res., 43: 1426–1431, 1983.
9.
HryniukW.M.: Average relative dose intensity and the impact on design of clinical trials. Semin. Oncol., 14: 65–74, 1987.
LeichmanL., BerryB.T.: Cisplatin therapy for adenocarcinoma of the stomach. Semin. Oncol., 18: 25–33, 1991.
12.
LeichmanL., SilbermanH., LeichmanC.G., SpearsC.P., RayM., MuggiaF.M., KiyabuM., RadinR., LaineL., StainS., FuerstM., GroshenS., DonovanA.: Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California Pilot Program. J. Clin. Oncol., 10: 1933–1942, 1992.
13.
MarkmanM.: Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat. Rev., 219–242, 1986.
14.
MartensM.F.W.C., HendriksT., WobbesT., De PontJ.J.H.H.M.: Intraperitoneal cytostatics impair early postoperative collagen synthesis in experimental intestinal anastomoses. Br. J. Cancer, 65: 649–654, 1992.
15.
MillerA.B., HoodgstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
16.
PiccartM.J., SpeyerJ.L., MarkmanM., ten Bokkel HuininkW.W., AlbertsD., JenkinsJ., MuggiaF.: Intraperitoneal chemotherapy: technical experience at five institutions. Semin. Oncol., 12: 90–96, 1985.
17.
SchilskyR.L., ChoiK.E., GrayhackJ., GrimmerD., GuarnieriC., FullemL.: Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J. Clin. Oncol., 8: 2054–2061, 1990.
18.
SilverbergE.: Cancer statistics. CA-Cancer J. Clin., 39: 3–20, 1989.
19.
SpeyerJ.L., SugarbakerP.H., CollinsJ.M., DedrickR.L., KleckerR.W., MyersC.E.: Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in human. Cancer Res., 4: 1916–1922, 1985.
20.
StuartG.C.E., NationJ.C., SniderD.D., ThunbergP.: Intraperitoneal interferon in the management of malignant ascites. Cancer, 71: 2027–2030, 1993.
21.
SugarbakerP.H., CunliffeW.J., BelliveauJ., de BruijnE.A., GravesT., MullinsR.E., SchlagP.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin. Oncol., 16: 83–97, 1989.
22.
TraveF., RustumY.M., FrankC.C., NavaH., DouglassH., SilkY., MazzoniA., ArbuckS.G.: Pharmacology of intraperitoneal high-dose 5-formyltetrahydrofolate in combination with 5FU in patients with intra-abdominal cancer. Proc. Am. Assoc. Cancer Res., 30: 966, 1989.
23.
WadlerS., SchwartzE.L.: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50: 3473–3486, 1990.
24.
WeedT.E., NuessleW., OchsnerA.: Carcinoma of the stomach: why are we failing to improve survival? Ann. Surg., 193: 407–413, 1981.
25.
WisbeckW.M., BecherE.M., RussellA.H.: Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother. Oncol., 7: 13–18, 1986.
